Results 241 to 250 of about 171,936 (295)

HPV‐6 Positive Eruptive Verruca Vulgaris After Upadacitinib Initiation for Severe Atopic Dermatitis

JEADV Clinical Practice, EarlyView.
ABSTRACT Oral JAK‐1 inhibitors for atopic dermatitis (AD) are associated with an increased risk of cutaneous viral infections, particularly herpes zoster. Emerging case reports further suggest a link to eruptive human papillomavirus (HPV) disease. A 23‐year‐old transgender man (female‐to‐male) with severe AD developed a rapidly disseminating eruption ...
Mohammed Shanshal, Emily Moon, Georgios Kallikas   +2 more
wiley   +1 more source

Risk Factors for Secondary Immunodeficiency in the Aged. [PDF]

J Allergy Clin Immunol Pract
Lang A, Grammatikos A, Ballow M, Otani I, Barmettler S.   +4 more
europepmc   +1 more source

Recurrent Respiratory Papillomatosis Foundation Position Statement on the Management of Adults With RRP

The Laryngoscope, EarlyView.
ABSTRACT Objective With regulatory approval of HPV‐specific immunotherapy for recurrent respiratory papillomatosis (RRP) and growing experience with systemic bevacizumab, a management algorithm incorporating these medical treatments is warranted. Data Sources and Methods RRP Foundation (RRPF) Key Opinion Leaders offer a proposed management algorithm ...
Simon R. Best, Aaron D. Friedman, Clark A. Rosen, Robert T. Sataloff, Laura A. Matrka, H. Steven Sims, David E. Rosow, Nabil F. Saba, David G. Lott, Adam M. Klein, Ted Mau, Milan R. Amin, Kathryn A. Wikenheiser‐Brokamp, Scott M. Norberg, Kim McClellan, Geoffrey D. Young, Clint T. Allen, on behalf of the Recurrent Respiratory Papillomatosis Foundation   +17 more
wiley   +1 more source

TTV Viremia and Immune Responses Following Vaccination Against Mpox and Dengue Viruses. [PDF]

Vaccines (Basel)
Minosse C, Spezia PG, Belladonna S, Bettini A, Matusali G, Colavita F, Notari S, Petrone L, Tiberi M, Cavasio AR, Mazzotta V, Rosa L, Cimini E, Focosi D, Goletti D, Nicastri E, Antinori A, Maggi F.   +17 more
europepmc   +1 more source

Cancer vaccines: comprehensive review. [PDF]

BJS Open
Clifford RE, Manu N, Yang Q, Arif Z, Aggen D, Bryan ME, Gupta A, Shaw H, Church D, Corrie P, Savelyeva N, Ottensmeier C, Danson S, Jones R.   +13 more
europepmc   +1 more source

‌An mRNA vaccine confers enhanced protection against herpes simplex virus through an IFN-I-dependent pathway. [PDF]

NPJ Vaccines
Zhao W, Sun L, Wang P, Zhao Q, Li Y, Li Y, Shi H, Xing M, Dai W, Zhou D.   +9 more
europepmc   +1 more source

How Deeply Can mRNA Vaccines Affect the Responsiveness to Immune Checkpoint Inhibitors Through Changes in the Tumor Microenvironment? Evidence from Melanoma. [PDF]

Cells
Persico I, Doro MG, Frogheri L, Sini MC, Maestrale GB, Manca A, Mallardo D, Ascierto PA, Palmieri G.   +8 more
europepmc   +1 more source

Harnessing <i>Toxoplasma gondii</i> microneme proteins for serodiagnosis and vaccine development: a review. [PDF]

Ann Med
Ji Y, Wang Z, Feng Y, Ahmad I, Alzahrani KJ, Alsharif KF, Alzahrani FM, Zhao X, Qadeer A, Liu W.   +9 more
europepmc   +1 more source

Trivalent coronavirus vaccines elicit broad-spectrum immunity in mice and attenuate respiratory viral load in golden hamsters. [PDF]

Front Immunol
Shen X, He J, Liu M, Zhang X, Wang P, Shao Y.   +5 more
europepmc   +1 more source

DNA vaccines

Seminars in Immunology, 1997
DNA vaccines use eukaryotic expression vectors to produce immunizing proteins in the vaccinated host. Popular methods of delivery are intramuscular and intradermal saline injections of DNA and gene gun bombardment of skin with DNA-coated gold beads.
Robinson, Harriet L., Torres, Celia Aurora Tiglao   +1 more
core   +11 more sources